Praetego Inc. and University of California San Diego scientists reported preclinical results for the new small-molecule amadorin PTG-630, a brain-penetrant drug candidate that inhibits the formation of advanced glycation end-products (AGEs).
Praetego Inc. has been granted a US$300,000 phase I Small Business Technology Transfer Research (STTR) award by the National Eye Institute (NEI) to advance the company's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.
Praetego Inc. has been awarded a US$2.5 million phase II Small Business Technology Transfer (STTR) award from the National Institute on Aging (NIA) to its advance lead candidate, PTG-630, for Alzheimer's disease.
